GSK’s messenger RNA vaccine for seasonal influenza is designed to prompt an immune response to two proteins on the surface of the virus. That could be an advantage over Moderna’s recently approved mRNA flu shot, which addresses just one of those proteins. The post GSK’s Pivotal Test for mRNA Flu Vaccine Aims to Show Two…
Join us for an upcoming Healthcare Innovation San Diego Summit panel exploring what’s real, what’s working and what healthcare leaders need to consider as AI moves from experimentation to action.
Faster trials are not a vanity metric. They reflect an undeniable need: getting safe therapies to patients sooner. The post Breaking the Amendment Cycle: How Agentic AI Enables Smarter Clinical Trial Design and Operations appeared first on MedCity News.
By FRANK LEAHY On a gray February morning, I sat in my office in Inverness, in rural northern California, with the phone pressed to my ear, jotting down notes and Humana reference numbers. Across the table, my new friend Rick, 77, waited anxiously, struggling to follow the conversation. Nearly deaf and now partially blind, Rick…
August has seen a slew of executive hires, exits and layoffs across the healthcare industry. For instance, Humana, Merck and Mayo Clinic named new executives. There were also layoffs at organizations including MaineHealth, Cellares and Sharp HealthCare. The post Healthcare Moves: A Monthly Summary of Hires, Exits and Layoffs appeared first on MedCity News.
In this episode, we’re joined by Amanda Shafton, practicing CNM and national director of midwifery at Ob Hospitalist Group. We discuss the benefits of physician/midwifery collaboration and how midwives can improve maternal health outcomes. The post MedCity FemFwd: How Midwives Can Support the Maternal Health Crisis appeared first on MedCity News.
Health tech companies made several major funding announcements in August. Here is a list of some of the biggest funding rounds. The post 4 Notable Health Tech Funding Announcements in August appeared first on MedCity News.
Impact Primary Care Network selected Innovaccer for its unified platform supporting care management and population health analytics
Recent incidents of rogue AI models infiltrating organizations underscore the growing threat
Takeda Pharmaceutical’s Mimrylo is now approved for treating polycythemia vera, a rare blood cancer with limited therapeutic options. Originally developed by Protagonist Therapeutics, the engineered peptide gives Takeda a drug with blockbuster sales potential as the pharma company’s top overall product faces patent expirations. The post First-in-Class Takeda, Protagonist Drug Lands FDA Approval in Rare…